FAQ on Calidi Biotherapeutics Inc.'s New CEO and Company Overview
Summary
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has appointed Eric Poma, PhD, as its new CEO to lead the company's next growth phase, leveraging his expertise in oncology and biotech to advance its innovative cancer therapies.
Who has been appointed as the new CEO of Calidi Biotherapeutics Inc.?
Eric Poma, PhD, has been appointed as the new chief executive officer and member of the board of directors of Calidi Biotherapeutics Inc.
Why is Eric Poma’s appointment significant for Calidi Biotherapeutics?
Dr. Poma’s extensive background in oncology, successful track record in fundraising and strategic partnerships, and comprehensive understanding of the biotech landscape position him to effectively steer Calidi’s innovative therapies through clinical development and toward commercialization.
What does Calidi Biotherapeutics specialize in?
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer, utilizing novel stem cell-based platforms for targeted antitumor virotherapies.
What are the key technologies or platforms of Calidi Biotherapeutics?
Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses, and its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors.
Where is Calidi Biotherapeutics headquartered?
Calidi Biotherapeutics is headquartered in San Diego, California.
How can I learn more about Calidi Biotherapeutics?
For more information, visit the company’s website at www.calidibio.com.
Where can I find the latest news and updates about Calidi Biotherapeutics?
The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI.
What is TinyGems?
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio @ IBN that delivers various services including access to a vast network of wire solutions and social media distribution.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 109531